In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: Suppression of retrovirus-induced immunodeficiency disease

Antiviral Research

Volumn 62, Issue 3, 2004, Pages 111-120

  Sumpter, L Ryan ^a   Inayat, Mohammed S ^a   Yost, Erin E ^a   Duvall, William ^a   Hagan, Espen ^a,b   Mayhew, Christopher N ^a   Elford, Howard L ^c   Gallicchio, Vincent S ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Molecules for Health Inc   (United States)

Author keywords

Abacavir; Didox; Hydroxyurea; Murine AIDS; Ribonucleotide reductase; Trimidox

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; ABACAVIR; ANTIRETROVIRUS AGENT; ENZYME INHIBITOR; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME INHIBITION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; IN VIVO CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; SPLENOMEGALY; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDINES; BONE MARROW CELLS; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELLS; HYDROXAMIC ACIDS; HYDROXYUREA; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; RIBONUCLEOTIDE REDUCTASES; SPLEEN; SPLENOMEGALY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 2342526590     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.11.007     Document Type: Article

References (56)

1. Bianchi V., Pontis E., Reichard P. Changes of deoxyribonucleoside triphosphates pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. 261(34):1986;16037-16042
2. Broud D., Piper J., Gallicchio V., Black P., Kunder S., Goldberg H., Elford H., Hall B., van't Riet B., Bacho M., Mayhew C., Papermaster S., Oakley O., Ussery M. Novel ribonucleotide reductase (RR) inhibitors, didox and trimidox, produce antiretroviral effects in the murine acquired immunodeficiency (MAIDS) and in the HIV-infected HuPBMC SCID models. Antiviral Res. 37:1998;A58. (Abstract)
3. Buller R.M., Yetter R.A., Fredrickson T.N., Morse H.C. III Abrogation of resistance to severe mousepox in C57BL6 mice infected with LP-BM5 murine leukemia viruses. J. Virol. 61(2):1987;383-387
4. Chattopadhyay S.K., Sengupta D.N., Fredrickson T.N., Morse H.C., Hartley J.W. Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice. J. Virol. 65(8):1991;4232-4241
5. Doherty T.M., Morse H.C., Coffman R.L. Modulation of specific T cell responses by concurrent infection with Leishmania major and LP-BM5 murine leukemia viruses. Int. Immunol. 7(1):1995;131-138
6. Dornadula G., Zhang H., Van Uitert B., Stern J., Livornese L. Jr., Ingerman M.J., Witek J., Dedanis R.J., Natkin J., DeSimone J., Pomerantz R.J. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282:1999;1627-1632
7. Elford H.L. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 33(1):1968;129-135
8. Elford H.L., van't Riet B. Inhibition of nucleoside diphosphates reductase by hydroxybenzohydroxamic acid derivatives. Pharmacol. Ther. 29(2):1985;239-254
9. Elford H.L., Wampler G.L., van't Riet B. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res. 39(3):1979;844-851
10. Elford H.L., van't Riet B., Wampler G.L., Lin A.L., Elford R.M. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Adv. Enzyme Regul. 19:1980;151-168
11. Foli A., Lori F., Maserati R., Tinelli C., Minoli L., Lisziewicz J. Hydroxyurea and didanosine as a more potent combination than hydroxyurea and zidovudine. Antivir. Ther. 2(1):1997;33-40
12. Fraternale A., Cassabianca A., Orlandi C., Chiarantini L., Brandi G., Silvestri G., Magnani M. Repeated cycles of alternate administration of fludarabine and zidovudine plus didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels. Virology. 302(2):2002;354-362
13. Galpin, J.E., Lori, F., Globe, D.R., Casciato, D., 1998. Safety, sheltering, & synergy of hydroxyurea (HU) with ddI or ddI plus d4T in HIV-infected patients. Fifth Conf. Retrovir. Oppor. Infect. (abstract no. 645).
14. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 90(19):1993;8925-8928
15. Gao W.Y., Johns D.G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′, 3′- dideoxynucleosides. Mol. Pharmacol. 46(4):1994;767-772
16. Gao W.Y., Zhou B.S., Johns D.G., Mitsuya H., Yen Y. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2′, 3′-dideoxyinosine. Biochem. Pharmacol. 56(1):1998;105-112
17. Giorgi J.V., Liu Z., Hultin L.E., Cumberland W.G., Hennessey K., Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune. Defic. Syndr. 6(8):1993;904-912
18. Johns D.G., Gao W.Y. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem. Pharmacol. 55(10):1998;1551-1556
19. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J. 5(10):1991;2398-2405
20. Klinman D.M., Morse H.C. Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142(4):1989;1144-1149
21. Laterjet R., Duplan J.F. Experiment and discussion on leukaemogenesis induced cell free extracts of radiation-induced leukaemia in mice. Int. J. Radiat. Biol. 5:1962;339-344
22. Lori R. Hydroxyurea and HIV: 5 years later-from antiviral to immune-modulating effects. AIDS. 13:1999;1422-1433
23. Lori F., Lisziewicz J. Hydroxyurea: mechanisms of HIV-1 inhibition. Antivir. Ther. 3(Suppl. 4):1998;25-33
24. Lori F., Malykh A., Cara A., Sun D., Weinstein J.N., Lisziewicz J., Gallo R.C. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science. 266(5186):1994;801-805
25. Lori F., Jessen H., Foli A., Lisziewicz J., Matteo P.S. Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA. 277(18):1997a;1437- 1438
26. Lori F., Malykh A., Foli A., Maserati R., De Antoni A., Minoli L., Padrini D., Antoni A., Barchi E., Jessen H., Wainberg M.A., Gallo R.C., Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. Hum. Retroviruses. 13(16):1997b;1403-1409
27. Lori F., Jessen H., Lieberman J., Clerici M., Tinelli C., Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res. Hum. Retroviruses. 15(7):1999a;619-624
28. Lori F., Jessen H., Lieberman J., Finzi D., Rosenberg E., Tinelli C., Walker B., Siliciano R.F., Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180(6):1999b;1827-1832
29. Magnani M., Fraternale A., Casabianca A., Schiavano G.F., Chiarantini L., Palamara A.T., Ciriolo M.R., Rotilio G., Garaci E. Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS. AIDS Res. Hum. Retroviruses. 13(13):1997;1093-1099
30. Malley S.D., Grange J.M., Hamedi-Sangsari F., Vila J.R. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′, 3′-dideoxyinosine in infected resting human lymphocytes. Prox. Natl. Acad. Sci. U.S.A. 91(23):1994;11017-11021
31. Maserati R. Hydroxyurea in the treatment of HIV-1 infection: toxicity and side effects. J. Biol. Regul. Homeost. Agents. 13(3):1999;181-185
32. Mayhew C., Oakley O., Piper J., Hughes N.K., Phillips J., Birch N.J., Elford H.L., Gallicchio V.S. Effective use of ribonucleotide reductase inhibitors (didox and trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). Cell. Mol. Biol. 43(7):1997;1019-1029
33. Mayhew C.N., Phillips J.D., Greenberg R.N., Birch N.J., Elford H.L., Gallicchio V.S. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells. 17(6):1999;345-356
34. Mayhew C.N., Phillips J.D., Cibull M.L., Elford H.L., Gallicchio V.S. Short-term treatment with novel ribonucleotide reductase inhibitors trimidox and didox reverses late-stage murine retrovirus-induced lymphoproliferativie disease with less bone marrow toxicity than hydroxyurea. Antivir. Chem. Chemother. 13(5):2002a;305-314
35. Mayhew C.N., Mampuru L.J., Chendil D., Ahmed M.M., Phillips J.D., Greenberg R.N., Elford H.L., Gallicchio V.S. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res. 56(2):2002b;167-181
36. Meyerhans A., Vartanian J.P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68(1):1994;535-540
37. Mills D.L., Elford H.L., van't Riet B. Didox and analogs are effective against retrovirus in a murine model. Antiviral Res. 17(Suppl. 1):1992a;76
38. Mills D.L., Elford H.L., van't Riet B. Didox exhibits antiviral activity in a retrovirus animal model. Proc. Am. Assoc. Cancer. Res. 33:1992b;399
39. Moore E.C., Hurlbert R.B. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol. Ther. 27(2):1985;167-196
40. Morse H.C., Chattopadhyay S.K., Makino M., Fredrickson T.N., Hugin A.W., Hartley J.W. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS. 6(7):1992;607-621
41. Neyts J., De Clerq E. Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 43(12):1999;2885-2892
42. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science. 260(5115):1993;1773-1777
43. Rutschmann O.T., Vernazza P.L., Bucher H.C., Opravil M., Ledergerber B., Telenti A., Malinverni R., Bernasconi E., Fagard C., Leduc D., Perrin L., Hirschel B. Long-term hydroxyurea in combination with didanosine and stuvadine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS. 14:2000;2145-2151
44. Shafer R.W., Winters M.A., Plamer S., Merigan T.C. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128:1998;906-911
45. Snyder R.D., Wawra E., Wintersberger E. Deoxyribonucleoside triphosphates pools in human diploid fibroblasts and their modulation by hydroxyurea and deoxynucleosides: does hydroxyurea inhibit DNA replication in mouse cells by more than one mechanism? Biochem. Pharmacol. 33(9):1984;1515-1518
46. Sommadossi J.P. Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16(Suppl. 1):1993;S7-S15
47. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9(5):1990;1551-1560
48. Suruga Y., Makino M., Okada Y., Tanaka H., De Clercq E., Baba M. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl) adenine. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 18(4):1998;316-322
49. Szekeres T., Fritzer M., Strobl H., Gharehbaghi K., Findenig G., Elford H.L., Lhotka C., Schoen H.J., Jayaram H.N. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofuring in human promyelocytic leukemia HL-60 cells. Blood. 84(12):1994a;4316-4321
50. Szekeres T., Gharehbaghi K., Fritzer M., Woody M., Srivastava A., van't Riet B., Jayaram H.N., Elford H.L. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 34(1):1994b;63-66
51. Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 48:1979;133-158
52. Tihan T., Elford H.L., Cory J.G. Studies on the mechanisms of inhibition of L1210 cell growth by 3, 4-dihydroxybenzohydroxamic acid and 3, 4-dihydroxybenzamidoxime. Adv. Enzyme Regul. 31:1991;71-83
53. Ussery M.A., Wood O.L., Broud D.D., Bacho M.A., Kunder S.C., Vona S.F., Nielsen C.J., Elford H.L. Didox, a novel ribonucleotide reductase inhibitor, is more active than hydroxyurea in HIV-infected HuPBMC SCID mice. Antivir. Ther. 4(Suppl. 1):1999;12. (abstract)
54. van't Riet B., Wampler G.L., Elford H.L. Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J. Med. Chem. 22(5):1979;589-592
55. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Adda N., Rozenbaum W., Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:1999;383-392
56. Zinkernagel R.M., Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol. Today. 15:1994;262-268